Tags

Type your tag names separated by a space and hit enter

Therapeutic Applications of Curcumin Nanoformulations.
AAPS J. 2015 Nov; 17(6):1341-56.AJ

Abstract

Curcumin (diferuloylmethane) is a bioactive and major phenolic component of turmeric derived from the rhizomes of curcuma longa linn. For centuries, curcumin has exhibited excellent therapeutic benefits in various diseases. Owing to its anti-oxidant and anti-inflammatory properties, curcumin plays a significant beneficial and pleiotropic regulatory role in various pathological conditions including cancer, cardiovascular disease, Alzheimer's disease, inflammatory disorders, neurological disorders, and so on. Despite such phenomenal advances in medicinal applications, the clinical implication of native curcumin is hindered due to low solubility, physico-chemical instability, poor bioavailability, rapid metabolism, and poor pharmacokinetics. However, these issues can be overcome by utilizing an efficient delivery system. Active scientific research was initiated in 2005 to improve curcumin's pharmacokinetics, systemic bioavailability, and biological activity by encapsulating or by loading curcumin into nanoform(s) (nanoformulations). A significant number of nanoformulations exist that can be translated toward medicinal use upon successful completion of pre-clinical and human clinical trials. Considering this perspective, current review provides an overview of an efficient curcumin nanoformulation for a targeted therapeutic option for various human diseases. In this review article, we discuss the clinical evidence, current status, and future opportunities of curcumin nanoformulation(s) in the field of medicine. In addition, this review presents a concise summary of the actions required to develop curcumin nanoformulations as pharmaceutical or nutraceutical candidates.

Links

PMC Free PDF

Authors+Show Affiliations

Yallapu MM
Department of Pharmaceutical Sciences and Center for Cancer Research, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA. myallapu@uthsc.edu.
Nagesh PK
Department of Pharmaceutical Sciences and Center for Cancer Research, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA.
Jaggi M
Department of Pharmaceutical Sciences and Center for Cancer Research, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA.
Chauhan SC
Department of Pharmaceutical Sciences and Center for Cancer Research, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA. myallapu@uthsc.edu.

MeSH

AnimalsAnti-Inflammatory AgentsChemistry, PharmaceuticalCurcuminDrug Delivery SystemsHumansNanotechnologyNeoplasmsNervous System Diseases

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review

Language

eng

PubMed ID

26335307

Citation

Yallapu, Murali M., et al. "Therapeutic Applications of Curcumin Nanoformulations." The AAPS Journal, vol. 17, no. 6, 2015, pp. 1341-56.
Yallapu MM, Nagesh PK, Jaggi M, et al. Therapeutic Applications of Curcumin Nanoformulations. AAPS J. 2015;17(6):1341-56.
Yallapu, M. M., Nagesh, P. K., Jaggi, M., & Chauhan, S. C. (2015). Therapeutic Applications of Curcumin Nanoformulations. The AAPS Journal, 17(6), 1341-56. https://doi.org/10.1208/s12248-015-9811-z
Yallapu MM, et al. Therapeutic Applications of Curcumin Nanoformulations. AAPS J. 2015;17(6):1341-56. PubMed PMID: 26335307.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic Applications of Curcumin Nanoformulations. AU - Yallapu,Murali M, AU - Nagesh,Prashanth K Bhusetty, AU - Jaggi,Meena, AU - Chauhan,Subhash C, Y1 - 2015/09/03/ PY - 2015/06/05/received PY - 2015/07/29/accepted PY - 2015/9/4/entrez PY - 2015/9/4/pubmed PY - 2016/8/19/medline KW - cancer KW - curcumin KW - drug delivery KW - nanoparticles KW - nanotechnology SP - 1341 EP - 56 JF - The AAPS journal JO - AAPS J VL - 17 IS - 6 N2 - Curcumin (diferuloylmethane) is a bioactive and major phenolic component of turmeric derived from the rhizomes of curcuma longa linn. For centuries, curcumin has exhibited excellent therapeutic benefits in various diseases. Owing to its anti-oxidant and anti-inflammatory properties, curcumin plays a significant beneficial and pleiotropic regulatory role in various pathological conditions including cancer, cardiovascular disease, Alzheimer's disease, inflammatory disorders, neurological disorders, and so on. Despite such phenomenal advances in medicinal applications, the clinical implication of native curcumin is hindered due to low solubility, physico-chemical instability, poor bioavailability, rapid metabolism, and poor pharmacokinetics. However, these issues can be overcome by utilizing an efficient delivery system. Active scientific research was initiated in 2005 to improve curcumin's pharmacokinetics, systemic bioavailability, and biological activity by encapsulating or by loading curcumin into nanoform(s) (nanoformulations). A significant number of nanoformulations exist that can be translated toward medicinal use upon successful completion of pre-clinical and human clinical trials. Considering this perspective, current review provides an overview of an efficient curcumin nanoformulation for a targeted therapeutic option for various human diseases. In this review article, we discuss the clinical evidence, current status, and future opportunities of curcumin nanoformulation(s) in the field of medicine. In addition, this review presents a concise summary of the actions required to develop curcumin nanoformulations as pharmaceutical or nutraceutical candidates. SN - 1550-7416 UR - https://www.unboundmedicine.com/medline/citation/26335307/Therapeutic_Applications_of_Curcumin_Nanoformulations_ DB - PRIME DP - Unbound Medicine ER -